🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsSide Effects & ManagementJoint pain improvement vs new joint pain — November 2025

Joint pain improvement vs new joint pain — November 2025

NurseLeah_Nash Sat, Nov 23, 2024 at 7:32 PM 11 replies 1,825 viewsPage 1 of 3
This thread is more than 18 months old. Information may be outdated. Consider searching for more recent discussions.
NurseLeah_Nash
Member
278
1,234
Sep 2024
Nashville, TN
Nov 23, 2024 at 7:32 PM#1

The nausea I get is not really nausea, it is an aversion. Food I want in the abstract becomes repellent in front of me, which no side-effect list describes.

Trial-level incidence runs roughly 20 to 25% for nausea at the higher dose tiers and 12 to 17% for diarrhoea, with most events mild to moderate and concentrated in the weeks after each escalation.

The bit I cannot resolve on my own is whether holding at a lower dose for longer actually reduces total side-effect burden or just spreads it out.

Not looking for reassurance. Looking for the part I have got wrong.

44 14RegAffairsDC, BiostatsBrad, PeptideSynthNJ and 41 others
Reply Quote Save Share Report
Dr.RenalNash
VIP Member
1,234
7,890
Mar 2024
Nashville, TN
Nov 23, 2024 at 9:56 PM#2

Short answer first, then the reasoning. The practical protocol is dull and it works: smaller meals, stop eating at the first sign of fullness rather than at the end of the plate, drop the fat fraction of meals in the two days after dosing, and do not lie down straight after eating. Most of what people call unmanageable nausea is a meal-size and meal-composition problem interacting with a stomach that is emptying slowly.

Last edited: Nov 24, 2024 at 2:56 AM
43 13pam_stl, wei_SG, cory_ATX and 40 others
Reply Quote Save Share Report
A1cHero_PHX
Member
523
2,678
Jul 2024
Phoenix, AZ
Nov 24, 2024 at 12:20 AM#3
Dr.RenalNash said:
The practical protocol is dull and it works: smaller meals, stop eating at the first sign of fullness rather than at the end of the plate, drop the…

Agreed on adaptation, with a caveat: adaptation applies to gastric emptying and not to everything. If your problem is the aversion rather than the fullness, waiting does less, because the aversion is central and it is the mechanism working as intended.

42 12tampaLisa73, KarenAZ_mom, zoe_NC and 39 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
zoe_NC
Member
278
1,234
Nov 2024
Charlotte, NC
Nov 24, 2024 at 2:44 AM#4
NurseLeah_Nash said:
The nausea I get is not really nausea, it is an aversion.

Can confirm the pattern NurseLeah_Nash describes. Holding genuinely reduces total burden rather than redistributing it, because the gastric-emptying component adapts. Receptor-level tachyphylaxis to the delayed-emptying effect develops over weeks while the central appetite effect persists, so the same dose is materially more comfortable at week six than at week two. A slower ladder therefore reaches the same dose with less cumulative nausea, not the same nausea spread thinner.

Last edited: Nov 24, 2024 at 3:44 AM
41 11NicoleRaleigh, james_edin, FranDenver and 38 others
Reply Quote Save Share Report
Dr.RaviCardio
VIP Member
2,890
15,678
Jan 2024
New York, NY
Nov 24, 2024 at 5:03 PM#5

Clinical perspective, offered as context rather than as advice. It helps to say which part of this you are uncertain about. A precise question gets a precise answer; a general one gets everybody’s favourite anecdote.

40 10jason_sac26, chris_chi24, tampaLisa73 and 37 others
Reply Quote Save Share Report

Similar Threads

Nausea incidence by dose tier — STEP and SURMOUNT meta-analysis16 replies
Constipation on GLP-1: pathophysiology and fiber protocol5 replies
Alopecia on GLP-1 — telogen effluvium differential diagnosis3 replies
Gallbladder disease risk — cholelithiasis data from clinical trials12 replies
Pancreatitis risk assessment — pooled safety analysis15 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register